Efficacy and safety of pharmacotherapy for cancer cachexia: A systematic review and network meta‐analysis
Open Access
- 3 September 2024
- journal article
- review article
- Published by Wiley in Cancer Medicine
- Vol. 13 (17) , e70166
Abstract
Background: Cancer cachexia affects more than half of all cancer patients, reducing survival rates. Evidence‐based approaches are urgently needed to optimize treatment.Methods: A systematic review and network meta‐analysis were conducted to assess the effectiveness and safety of different pharmacotherapies for cancer cachexia. Three databases (PubMed, Cochrane Library, and Web of Science) were searched for the period from January 1, 2000, to March 20, 2024. The netmeta package in R software was used to calculate the pooled effect, employing a random effects model.Results: Seven placebo‐controlled randomized trials involving 1421 patients were analyzed. Pairwise analysis showed that body weight increases were 4.6 kg (95% confidence interval [CI] 0.83–8.37 kg) for olanzapine, 3.82 kg (95% CI 0.73–6.91 kg) for espindolol (20 mg), 2.36 kg (95% CI 1.84–2.89 kg) for anamorelin (100 mg), and 1.31 kg (95% CI 0.42–2.19 kg) for anamorelin (50 mg). In terms of safety profiles, olanzapine demonstrated the lowest odds ratio when compared to placebo, at 0.26 (95% CI 0.07–0.94), followed by anamorelin (50 mg) at 0.86 (95% CI 0.30–2.48), and anamorelin (100 mg) at 0.89 (95% CI 0.42–1.88). However, network meta‐analysis could not confirm the superiority of olanzapine over anamorelin in terms of efficacy and safety.Conclusion: Both olanzapine and anamorelin are useful in improving body weight in patients with cancer cachexia. Personalization may be helpful for different patients.Keywords
This publication has 29 references indexed in Scilit:
- ESPEN guidelines on nutrition in cancer patientsClinical Nutrition, 2017
- Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial)Journal of Cachexia, Sarcopenia and Muscle, 2016
- Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trialsThe Lancet Oncology, 2016
- Pentoxifylline treatment in patients with cancer cachexia: A double-blind, randomized, placebo-controlled clinical trialAdvanced Biomedical Research, 2016
- Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trialThe Lancet Oncology, 2013
- Toward a sex‐specific relationship between muscle strength and appendicular lean body mass index?Journal of Cachexia, Sarcopenia and Muscle, 2013
- Pathophysiology of the anorexia of agingCurrent Opinion in Clinical Nutrition and Metabolic Care, 2013
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- Olanzapine‐Associated Diabetes MellitusPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002